March 6th brought the announcement of a pair of Med Tech IPOs:
KMTS (Kestra Medical Technologies) 11.9M share IPO (upsized from 10M) priced at $17/share, above the anticipated range of $14-16/shr. Scheduled to begin trading on the Nasdaq at 10:20ET. Kestra is a developer of wearable cardiac devices (MedTech) - S-1
ADVB (Advanced Biomed) 1.6M shares IPO (downsized from 1.9M) priced at $4/share, the low-end of the anticipated range of $4-6/shr. Scheduled to begin trading on the Nasdaq at 10:45ET. Advanced Biomed is a developer of diagnostic tests for early cancer detection (MedTech) - S-1
On March 5th, Jazz Pharmaceuticals announced the acquisition of Chimerix for $935M or $8.55/share; a premium of 72%.
Capital Markets Update:
2025 YTD (Week Ending 2/28/2025):
24 Biotech transactions totaling just under $4B vs. 2024 YTD: 71 Biotech transactions totaling just under $14B
7 Med Tech transactions totaling just under $700M vs. 2024 YTD: 2 Med Tech transactions totaling just under $200M
Commenti